EBNA3C-mediated regulation of aurora kinase b contributes to epstein-barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases

Journal of Virology

Volumn 87, Issue 22, 2013, Pages 12121-12138

  Jha, Hem Chandra ^a   Lu, Jie ^a   Saha, Abhik ^a   Cai, Qiliang ^a   Banerjee, Shuvomoy ^a   Prasad, Mahadesh A J ^a   Robertson, Erle S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA B KINASE; CASPASE; CASPASE 3; CASPASE 9; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3C; MUTANT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLOGY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPSTEIN BARR VIRUS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR BLEBBING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; CELL CYCLE; CELL NUCLEUS; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; EPSTEIN BARR VIRUS INFECTION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PATHOGENICITY; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; WESTERN BLOTTING;

HUMAN HERPESVIRUS 4; MAMMALIA;

ANIMALS; APOPTOSIS; AURORA KINASE B; B-LYMPHOCYTES; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOPRECIPITATION; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; UBIQUITINATION;

EID: 84886303037     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02379-13     Document Type: Article

References (82)

1. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i:702-703.
2. Henle W, Henle G, Lennette ET. 1979. The Epstein-Barr virus. Sci. Am. 241:48-59.
3. Young LS, Murray PG. 2003. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108-5121.
4. Xing L, KieffE. 2007. Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication. J. Virol. 81:9967-9975.
5. Sinclair AJ, Palmero I, Peters G, Farrell PJ. 1994. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:3321-3328.
6. Knight JS, Robertson ES. 2004. Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J. Virol. 78:1981-1991.
7. Knight JS, Sharma N, Kalman DE, Robertson ES. 2004. A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclinAand modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J. Virol. 78:12857-12867.
8. Knight JS, Sharma N, Robertson ES. 2005. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol. Cell. Biol. 25:1749-1763.
9. Hollyoake M, Stuhler A, Farrell P, Gordon J, Sinclair A. 1995. The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Res. 55:4784-4787.
10. Saha A, Halder S, Upadhyay SK, Lu J, Kumar P, Murakami M, Cai Q, Robertson ES. 2011. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog. 7:e1001275. doi:10.1371/journal.ppat.1001275.
11. Keen N, Taylor S. 2004. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4:927-936.
12. Carvajal RD, Tse A, Schwartz GK. 2006. Aurora kinases: new targets for cancer therapy. Clin. Cancer Res. 12:6869-6875.
13. Zeitlin SG, Shelby RD, Sullivan KF. 2001. CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis. J. Cell Biol. 155:1147-1157.
14. Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, Liu Q. 2008. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncol. 44:639-645.
15. Ruchaud S, Carmena M, Earnshaw WC. 2007. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 8:798-812.
16. Sessa F, Mapelli M, Ciferri C, Tarricone C, Areces LB, Schneider TR, Stukenberg PT, Musacchio A. 2005. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol. Cell 18:379-391.
17. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. 2009. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J. Virol. 83: 4652-4669.
18. Kimura M, Uchida C, Takano Y, Kitagawa M, Okano Y. 2004. Cell cycle-dependent regulation of the human Aurora B promoter. Biochem. Biophys. Res. Commun. 316:930-936.
19. Zhao B, Sample CE. 2000. Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J. Virol. 74:5151-5160.
20. Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, Keen N, Schwartz GK. 2009. Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol. Biol. Cell 20:2218-2228.
21. Hochegger H, Hegarat N, Pereira-Leal JB. 2013. Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol. 3:120185.
22. Normand G, King RW. 2010. Understanding cytokinesis failure. Adv. Exp. Med. Biol. 676:27-55.
23. Parker GA, Touitou R, Allday MJ. 2000. Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19:700-709.
24. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. 2009. Centrosomeassociated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol. Cancer 8:8.
25. Murata-Hori M, Wang YL. 2002. The kinase activity of Aurora B is required for kinetochore-microtubule interactions during mitosis. Curr. Biol. 12:894-899.
26. Yoon MJ, Park SS, Kang YJ, Kim IY, Lee JA, Lee JS, Kim EG, Lee CW, Choi KS. 2012. Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin. Carcinogenesis 33:492-500.
27. Cai Q, Xiao B, Si H, Cervini A, Gao J, Lu J, Upadhyay SK, Verma SC, Robertson ES. 2012. Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog. 8:e1002566. doi:10.1371/journal.ppat.1002566.
28. Wheatley SP, Henzing AJ, Dodson H, Khaled W, Earnshaw WC. 2004. Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J. Biol. Chem. 279:5655-5660.
29. Saha A, Halder S, Upadhyay SK, Lu J, Kumar P, Murakami M, Cai Q, Robertson ES. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog. 7:e1001275. doi:10.1371/journal.ppat.1001275.
30. Cai Q, Guo Y, Xiao B, Banerjee S, Saha A, Lu J, Glisovic T, Robertson ES. 2011. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog. 7:e1002418. doi:10.1371/journal.ppat.1002418.
31. Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, Robertson ES. 2012. E2F1 mediated apoptosis induced by theDNAdamage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog. 8:e1002573. doi:10.1371/journal.ppat.1002573.
32. Brummelkamp TR, Bernards R, Agami R. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
33. Honda R, Korner R, Nigg EA. 2003. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol. Biol. Cell 14:3325-3341.
34. Gao J, Cai Q, Lu J, Jha HC, Robertson ES. 2011. Upregulation of cellular Bcl-2 by the KSHV encoded RTA promotes virion production. PLoS One 6:e23892. doi:10.1371/journal.pone.0023892.
35. Jha HC, Upadhyay SK, AJPM, Lu J, Cai Q, Saha A, Robertson ES. 2013. H2AX phosphorylation is important for LANA-mediated Kaposi's sarcoma-associated herpesvirus episome persistence. J. Virol. 87:5255-5269.
36. Fu J, Bian M, Jiang Q, Zhang C. 2007. Roles of Aurora kinases in mitosis and tumorigenesis. Mol. Cancer Res. 5:1-10.
37. Ning S, Hahn AM, Huye LE, Pagano JS. 2003. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J. Virol. 77:9359-9368.
38. Kim HJ, Cho JH, Quan H, Kim JR. 2011. Down-regulation of Aurora B kinase induces cellular senescence in human fibroblasts and endothelial cells through a p53-dependent pathway. FEBS Lett. 585:3569-3576.
39. Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. 2000. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J. Biol. Chem. 275:7337-7342.
40. Zhang Y, Xiong Y. 2001. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292:1910-1915.
41. Vargas J, Jr, Gusella GL, Najfeld V, Klotman ME, Cara A. 2004. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum. Gene Ther. 15:361-372.
42. Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, Yamamoto T, Nagano A, Kawai G, Matsuhashi A, Saitoh M, Takigami I, Okano Y, Shimizu K. 2008. EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases. Mol. Cancer Res. 6:1937-1945.
43. Wang Y, Zhou BP. 2012. FBW7-Aurora B-p53 feedback loop regulates mitosis and cell growth. Cell Cycle 11:4113-4114.
44. Kojima K, Konopleva M, Tsao T, Nakakuma H, AndreeffM. 2008. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 112:2886-2895.
45. Maerki S, Olma MH, Staubli T, Steigemann P, Gerlich DW, Quadroni M, Sumara I, Peter M. 2009. The Cul3-KLHL21 E3 ubiquitin ligase targets aurora B to midzone microtubules in anaphase and is required for cytokinesis. J. Cell Biol. 187:791-800.
46. Nguyen HG, Chinnappan D, Urano T, Ravid K. 2005. Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol. Cell. Biol. 25: 4977-4992.
47. Miao H, Jin X, Perelson AS, Wu H. 2012. Evaluation of multitype mathematical models for CFSE-labeling experiment data. Bull. Math. Biol. 74:300-326.
48. Lowe SW, Lin AW. 2000. Apoptosis in cancer. Carcinogenesis 21:485-495.
49. Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR. 2006. Acridine orange/ethidium bromide (AO/EB) staining to detect apoptosis. CSH Protoc. doi:10.1101/pdb.prot4493.
50. Ribble D, Goldstein NB, Norris DA, Shellman YG. 2005. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 5:12.
51. Chaitanya GV, Steven AJ, Babu PP. 2010. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun. Signal. 8:31.
52. Klein UR, Nigg EA, Gruneberg U. 2006. Centromere targeting of the chromosomal passenger complex requires a ternary subcomplex of Borealin, Survivin, and the N-terminal domain of INCENP. Mol. Biol. Cell 17:2547-2558.
53. van der Waal MS, Hengeveld RC, van der Horst A, Lens SM. 2012. Cell division control by the chromosomal passenger complex. Exp. Cell Res. 318:1407-1420.
54. Chen TC, Lee SA, Hong TM, Shih JY, Lai JM, Chiou HY, Yang SC, Chan CH, Kao CY, Yang PC, Huang CY. 2009. From midbody proteinprotein interaction network construction to novel regulators in cytokinesis. J. Proteome Res. 8:4943-4953.
55. Hegyi K, Mehes G. 2012. Mitotic failures in cancer: Aurora B kinase and its potential role in the development of aneuploidy. Pathol. Oncol. Res. 18:761-769.
56. Fichter CD, Herz C, Munch C, Opitz OG, Werner M, Lassmann S. 2011. Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells. BMC Cell Biol. 12:13.
57. Knight JS, Sharma N, Robertson ES. 2005. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 102:18562-18566.
58. Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, Choudhuri T, Robertson ES. 2009. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388: 236-247.
59. Saha A, Bamidele A, Murakami M, Robertson ES. 2011. EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J. Virol. 85:2079-2088.
60. Cohen JI, Wang F, Mannick J, KieffE. 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. U. S. A. 86:9558-9562.
61. Tomkinson B, Robertson E, KieffE. 1993. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67:2014-2025.
62. Zhao B, Dalbies-Tran R, Jiang H, Ruf IK, Sample JT, Wang F, Sample CE. 2003. Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses. J. Virol. 77:5639-5648.
63. Meyer H, Drozdowska A, Dobrynin G. 2010. A role for Cdc48/p97 and Aurora B in controlling chromatin condensation during exit from mitosis. Biochem. Cell Biol. 88:23-28.
64. Stewart S, Fang G. 2005. Destruction box-dependent degradation of aurora B is mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer Res. 65:8730-8735.
65. Adams RR, Wheatley SP, Gouldsworthy AM, Kandels-Lewis SE, Carmena M, Smythe C, GerloffDL, Earnshaw WC. 2000. INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow. Curr. Biol. 10:1075-1078.
66. Chu Y, Yao PY, Wang W, Wang D, Wang Z, Zhang L, Huang Y, Ke Y, Ding X, Yao X. 2011. Aurora B kinase activation requires survivin priming phosphorylation by PLK1. J. Mol. Cell Biol. 3:260-267.
67. BischoffJR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD. 1998. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17:3052-3065.
68. Warner SL, Bearss DJ, Han H, Von HoffDD. 2003. Targeting Aurora-2 kinase in cancer. Mol. Cancer Ther. 2:589-595.
69. Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf TH. 2009. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 11:934-944.
70. Bezabeh T, Mowat MR, Jarolim L, Greenberg AH, Smith IC. 2001. Detection of drug-induced apoptosis and necrosis in human cervical carcinoma cells using 1H NMR spectroscopy. Cell Death Differ. 8:219-224.
71. Gong Y, Li Y, Abdolmaleky HM, Li L, Zhou JR. 2012. Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. PLoS One 7:e33656. doi:10.1371/journal.pone.0033656.
72. Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtjarn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML. 2013. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia 27:560-568.
73. Li M, Jung A, Ganswindt U, Marini P, Friedl A, Daniel PT, Lauber K, Jendrossek V, Belka C. 2010. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem. Pharmacol. 79:122-129.
74. Belov GA, Romanova LI, Tolskaya EA, Kolesnikova MS, Lazebnik YA, Agol VI. 2003. The major apoptotic pathway activated and suppressed by poliovirus. J. Virol. 77:45-56.
75. Manns J, Daubrawa M, Driessen S, Paasch F, Hoffmann N, Loffler A, Lauber K, Dieterle A, Alers S, Iftner T, Schulze-OsthoffK, Stork B, Wesselborg S. 2011. Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1. FASEB J. 25:3250-3261.
76. Nobel CS, Burgess DH, Zhivotovsky B, Burkitt MJ, Orrenius S, Slater AF. 1997. Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Chem. Res. Toxicol. 10:636-643.
77. Ravid T, Tsaba A, Gee P, Rasooly R, Medina EA, Goldkorn T. 2003. Ceramide accumulation precedes caspase-3 activation during apoptosis of A549 human lung adenocarcinoma cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:L1082-L1092.
78. Shi Y. 2001. A structural view of mitochondria-mediated apoptosis. Nat. Struct. Biol. 8:394-401.
79. Chang HY, Yang X. 2000. Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 64:821-846.
80. Kroemer G, Galluzzi L, Brenner C. 2007. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87:99-163.
81. Andrade R, Crisol L, Prado R, Boyano MD, Arluzea J, Arechaga J. 2010. Plasma membrane and nuclear envelope integrity during the blebbing stage of apoptosis: a time-lapse study. Biol. Cell 102:25-35.
82. Elmore S. 2007. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35:495-516.